Tricuspid regurgitation is comparatively a common anomaly. Structural modifications of any or all of the tricuspid valve apparatus may cause the development of tricuspid regurgitation.
Anatomy
The right atrioventricular valve apparatus, or tricuspid valve, consists of the following components:
The conduction system and the supporting structure of the fibroelastic cardiac skeleton coordinate the actions of the tricuspid valve. The tricuspid valve is located between the right atrium and the right ventricle. It has a valve area of 4 to 6 cm2.[4]
The pathophysiological variants of the tricuspid valve include:
The lesions in tricuspid regurgitation may be categorized as primary where the intrinsic abnormalities in the tricuspid valvular apparatus are responsible or secondary where the right ventricular dilatation causes tricuspid regurgitation. Secondary disorders like tricuspid annular dilation and/or leaflet tethering in the setting of right ventricular pressure and/or volume overload are largely responsible for tricuspid regurgitation as compared to primary disorders involving the valve apparatus. [5],[6],[7]
Secondary Tricuspid Regurgitation
In adults, tricuspid regurgitation is most commonly secondary with probable normal anatomical leaflets and chords. Dilatation of the right atrium, the right ventricle, along with dilatation of the tricuspid annulus[8], and tethering of the tricuspid valve leaflet are some of the causes of secondary tricuspid regurgitation. This may result due to conditions affecting the right ventricle or may be due to an increase in right ventricle systolic pressure often with pulmonary hypertension. The valves are anatomically normal, but because of the enlarged right ventricular cavity and dilatation of the annulus, the leaflets fail to coapt appropriately.
Conditions affecting the right ventricle that eventually cause tricuspid regurgitation include cardiomyopathies and ischemic heart diseases involving the right ventricular myocardium and tricuspid papillary muscles.[9]
The conditions that induce pulmonary hypertension and secondary RV dilatation include the following:
Primary Tricuspid Regurgitation
In adolescents and young adults, the cause of tricuspid regurgitation is usually congenital, but in adults, conditions that directly affect the tricuspid valvular apparatus are rare.
Causes of primary TR include:
The incidence of tricuspid regurgitation in the United States is found to be 0.9%. No gender or racial differences in the incidences are noted.
Tricuspid regurgitation presents at different age groups depending on its etiology. Ebstein anomaly may be diagnosed at birth and during early childhood. Rheumatic valvular disease is the most common form of tricuspid regurgitation in patients older than 15 years.
Primary structural abnormalities of the tricuspid valvular apparatus or secondary abnormalities due to myocardial dysfunction or dilatation are responsible for the structural incompetence of the tricuspid valve.[14] Tricuspid regurgitation is defined by the backflow of blood from the right ventricle into the right atrium during systole. In mild to moderate cases of tricuspid regurgitation, no major hemodynamic consequences are noted due to the comparatively compliant nature of the right atrium. However, in severe cases, right ventricular volume overload develops that eventually results in right-sided congestive heart failure presenting with peripheral edema, ascites, and hepatic congestion.
The severity of tricuspid regurgitation is increased during inspiration. The right ventricle widens during inspiration, which further enlarges the tricuspid valve annulus, hence increasing the effective regurgitant orifice area.[15]
Symptoms
Patients present with clinical features of right-sided heart failure. These may be painful hepatosplenomegaly, ascites, and peripheral edema. In severe cases, pulsations in the neck from the distended and pulsatile jugular veins is noted. Exercise intolerance may be seen. Clinical features of the underlying condition causing tricuspid regurgitation may be observed. For example, pulmonary hypertension may cause symptoms such as weakness, shortness of breath, and exercise intolerance or patients presenting with infective endocarditis, a common cause of tricuspid regurgitation, may present with febrile episodes.
Physical Examination
The main modality used to diagnose and evaluate tricuspid regurgitation is Doppler echocardiography. It is used to precisely contemplate regurgitant blood flow and its flow velocity and accurately measure the systolic pressure in the right ventricle
Echocardiographic Findings
Additional Tests
Chest Radiography: The following findings are noted:
Serum Chemistry: Abnormal liver function test, hyperbilirubinemia secondary to hepatic congestion may be noted.
Electrocardiography: Nonspecific ST and T waves in the right precordial leads reflecting right ventricular dysfunction seen. If pulmonary hypertension causes tricuspid regurgitation, the ECG may show right axis deviation indicating RV hypertrophy and tall R waves in V1 to V2. In severe pulmonary hypertension, right atrial hypertrophy and "P-pulmonale" may also be present.
Cardiac Catheterization: Elevated end-diastolic pressures in the right atrium and right ventricle are noted.
The preference of treatment depends on the severity of tricuspid regurgitation, etiology, and the presence and the extent of associated abnormalities including pulmonary hypertension, heart failure, and other valve conditions.
Management of severe tricuspid regurgitation includes medical therapy, counseling regarding pregnancy and physical activity, consideration of tricuspid valve surgery, and evaluation and treatment of the underlying cause.
Medical Treatment
In patients with tricuspid regurgitation secondary to left-sided heart failure, adequate control of fluid overload is indicated. Diuretics are suggested in these cases. Loop diuretics are commonly used. Restricted intake of salt is indicated. The head of the bed should be elevated as it may improve dyspnea. Digitalis, potassium-sparing diuretics, angiotensin-converting enzyme inhibitors and anticoagulants are indicated in these patients. Atrial fibrillation, if present, can be controlled by starting the patients on antiarrhythmics.
The following medications are used:
Tricuspid Valve Surgery
Indications for tricuspid valve surgery depend upon whether surgery for left-sided (aortic or mitral) valve disease is indicated
For patients undergoing left-sided valve surgery:
Isolated Tricuspid Surgery
The appropriate timing of isolated tricuspid valve surgery is not well established.
In patients who are refractory to medical treatment but have severe tricuspid regurgitation, tricuspid valve surgery is suggested (weak recommendation). It is preferred to perform it before the onset of significant right ventricular dysfunction to control or prevent symptoms, as recommended in the 2014 AHA/ACC valvular guidelines.[21]
In symptomatic and severe isolated tricuspid regurgitation without right ventricular dysfunction, tricuspid valve surgery is strongly recommended as per the 2012 ESC valvular guidelines.[22]
In asymptomatic or minimally symptomatic patients with severe TR, the role of tricuspid valve surgery is ambiguous. The 2014 AHA/ACC valvular guidelines note this uncertainty and include a very weak recommendation that tricuspid valve surgery may be considered for asymptomatic or minimally symptomatic patients with severe primary tricuspid regurgitation and progressive moderate or greater RV dilation and/or systolic dysfunction.[21]. The ESC guidelines view surgery in this setting slightly more favorably and indicate that surgery should be considered in patients with severe isolated tricuspid regurgitation with mild or no symptoms and progressive right ventricular dilation or deterioration of right ventricular function.[22]
Treatment Based on the Etiology
In tricuspid valve endocarditis, it is recommended to excise the tricuspid valve without immediate replacement. The excision of the diseased valve wipes out the endocarditis while the antibiotic treatment is continued. An artificial valve can be inserted if the right heart failure symptoms are refractory to medical management and the infection is well controlled.
In Ebstein anomaly, no surgery is needed in asymptomatic tricuspid regurgitation. However, symptomatic patients may need to be treated with the tricuspid valve repair or replacement.
The differential diagnosis of tricuspid regurgitation are as follows:
Prognosis of tricuspid regurgitation is generally good.
Complications include:
Complications of operative interventions include:
Further inpatient care of a patient with tricuspid regurgitation involves:
In patients whose valve has been removed, repeat echocardiography is indicated at 6-month intervals. In patients whose valve has been replaced, annual echocardiography is recommended.
The diagnosis and management of tricuspid regurgitation is with an interprofessional team consisting of a cardiologist, cardiac surgeon, internist, primary care provider, and nurse practitioner. The preference of treatment depends on the severity of tricuspid regurgitation, etiology, and the presence and the extent of associated abnormalities including pulmonary hypertension, heart failure, and other valve conditions.
Management of severe tricuspid regurgitation includes medical therapy, counseling regarding pregnancy and physical activity, consideration of tricuspid valve surgery, and evaluation and treatment of the underlying cause.
Mild cases are usually managed medically but severe cases require open heart surgery. The tricuspid valve can be repaired or replaced depending on the status of the leaflets. Because of the risk of thrombosis, all mechanical valves in the tricuspid position need anticoagulation. Patients need to be monitored for INR regularly. The outcomes of tricuspid regurgitation are usually fair to good. [23](Level V)
[1] | Wafae N,Hayashi H,Gerola LR,Vieira MC, Anatomical study of the human tricuspid valve. Surgical and radiologic anatomy : SRA. 1990 [PubMed PMID: 2345895] |
[2] | Aktas EO,Govsa F,Kocak A,Boydak B,Yavuz IC, Variations in the papillary muscles of normal tricuspid valve and their clinical relevance in medicolegal autopsies. Saudi medical journal. 2004 Sep [PubMed PMID: 15448762] |
[3] | Xanthos T,Dalivigkas I,Ekmektzoglou KA, Anatomic variations of the cardiac valves and papillary muscles of the right heart. Italian journal of anatomy and embryology = Archivio italiano di anatomia ed embriologia. 2011 [PubMed PMID: 22303639] |
[4] | Rogers JH,Bolling SF, The tricuspid valve: current perspective and evolving management of tricuspid regurgitation. Circulation. 2009 May 26 [PubMed PMID: 19470900] |
[5] | Nath J,Foster E,Heidenreich PA, Impact of tricuspid regurgitation on long-term survival. Journal of the American College of Cardiology. 2004 Feb 4 [PubMed PMID: 15013122] |
[6] | Mutlak D,Lessick J,Reisner SA,Aronson D,Dabbah S,Agmon Y, Echocardiography-based spectrum of severe tricuspid regurgitation: the frequency of apparently idiopathic tricuspid regurgitation. Journal of the American Society of Echocardiography : official publication of the American Society of Echocardiography. 2007 Apr [PubMed PMID: 17400120] |
[7] | Tornos Mas P,Rodríguez-Palomares JF,Antunes MJ, Secondary tricuspid valve regurgitation: a forgotten entity. Heart (British Cardiac Society). 2015 Nov [PubMed PMID: 26503944] |
[8] | Sagie A,Schwammenthal E,Padial LR,Vazquez de Prada JA,Weyman AE,Levine RA, Determinants of functional tricuspid regurgitation in incomplete tricuspid valve closure: Doppler color flow study of 109 patients. Journal of the American College of Cardiology. 1994 Aug [PubMed PMID: 8034882] |
[9] | Navia JL,Elgharably H,Javadikasgari H,Ibrahim A,Koprivanac M,Lowry AM,Blackstone EH,Klein AL,Gillinov AM,Roselli EE,Svensson LG, Tricuspid Regurgitation Associated With Ischemic Mitral Regurgitation: Characterization, Evolution After Mitral Surgery, and Value of Tricuspid Repair. The Annals of thoracic surgery. 2017 Aug [PubMed PMID: 28223050] |
[10] | Simula DV,Edwards WD,Tazelaar HD,Connolly HM,Schaff HV, Surgical pathology of carcinoid heart disease: a study of 139 valves from 75 patients spanning 20 years. Mayo Clinic proceedings. 2002 Feb [PubMed PMID: 11838647] |
[11] | Waller BF,Howard J,Fess S, Pathology of tricuspid valve stenosis and pure tricuspid regurgitation--Part III. Clinical cardiology. 1995 Apr [PubMed PMID: 7788951] |
[12] | Pritchett AM,Morrison JF,Edwards WD,Schaff HV,Connolly HM,Espinosa RE, Valvular heart disease in patients taking pergolide. Mayo Clinic proceedings. 2002 Dec [PubMed PMID: 12479512] |
[13] | Baseman DG,O'Suilleabhain PE,Reimold SC,Laskar SR,Baseman JG,Dewey RB Jr, Pergolide use in Parkinson disease is associated with cardiac valve regurgitation. Neurology. 2004 Jul 27 [PubMed PMID: 15277624] |
[14] | Frater R, Tricuspid insufficiency. The Journal of thoracic and cardiovascular surgery. 2001 Sep [PubMed PMID: 11547290] |
[15] | Topilsky Y,Tribouilloy C,Michelena HI,Pislaru S,Mahoney DW,Enriquez-Sarano M, Pathophysiology of tricuspid regurgitation: quantitative Doppler echocardiographic assessment of respiratory dependence. Circulation. 2010 Oct 12 [PubMed PMID: 20876436] |
[16] | Ha JW,Chung N,Jang Y,Rim SJ, Tricuspid stenosis and regurgitation: Doppler and color flow echocardiography and cardiac catheterization findings. Clinical cardiology. 2000 Jan [PubMed PMID: 10680030] |
[17] | Shah PM,Raney AA, Tricuspid valve disease. Current problems in cardiology. 2008 Feb [PubMed PMID: 18222317] |
[18] | Baumgartner H,Falk V,Bax JJ,De Bonis M,Hamm C,Holm PJ,Iung B,Lancellotti P,Lansac E,Rodriguez Muñoz D,Rosenhek R,Sjögren J,Tornos Mas P,Vahanian A,Walther T,Wendler O,Windecker S,Zamorano JL, 2017 ESC/EACTS Guidelines for the management of valvular heart disease. European heart journal. 2017 Sep 21 [PubMed PMID: 28886619] |
[19] | Nishimura RA,Otto CM,Bonow RO,Carabello BA,Erwin JP 3rd,Fleisher LA,Jneid H,Mack MJ,McLeod CJ,O'Gara PT,Rigolin VH,Sundt TM 3rd,Thompson A, 2017 AHA/ACC Focused Update of the 2014 AHA/ACC Guideline for the Management of Patients With Valvular Heart Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation. 2017 Jun 20 [PubMed PMID: 28298458] |
[20] | Antunes MJ,Rodríguez-Palomares J,Prendergast B,De Bonis M,Rosenhek R,Al-Attar N,Barili F,Casselman F,Folliguet T,Iung B,Lancellotti P,Muneretto C,Obadia JF,Pierard L,Suwalski P,Zamorano P, Management of tricuspid valve regurgitation: Position statement of the European Society of Cardiology Working Groups of Cardiovascular Surgery and Valvular Heart Disease. European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery. 2017 Dec 1 [PubMed PMID: 28950325] |
[21] | Nishimura RA,Otto CM,Bonow RO,Carabello BA,Erwin JP 3rd,Guyton RA,O'Gara PT,Ruiz CE,Skubas NJ,Sorajja P,Sundt TM 3rd,Thomas JD, 2014 AHA/ACC guideline for the management of patients with valvular heart disease: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Journal of the American College of Cardiology. 2014 Jun 10 [PubMed PMID: 24603191] |
[22] | Vahanian A,Alfieri O,Andreotti F,Antunes MJ,Barón-Esquivias G,Baumgartner H,Borger MA,Carrel TP,De Bonis M,Evangelista A,Falk V,Iung B,Lancellotti P,Pierard L,Price S,Schäfers HJ,Schuler G,Stepinska J,Swedberg K,Takkenberg J,Von Oppell UO,Windecker S,Zamorano JL,Zembala M, Guidelines on the management of valvular heart disease (version 2012). European heart journal. 2012 Oct [PubMed PMID: 22922415] |
[23] | Zhang FE,Li JY,Bo P,Zhang JQ,Ren T,Cao XR, [Midterm outcomes of surgical treatment of traumatic severe tricuspid insufficiency]. Zhonghua wai ke za zhi [Chinese journal of surgery]. 2019 Feb 1; [PubMed PMID: 30704218] |